In this study, the new GLP-1 receptor agonist lixisenatide significantly improved glycaemic control from a mildly elevated mean baseline HbA1c [∼7.55% (∼59.0 mmol/mol)] in patients with Type 2 diabetes mellitus inadequately controlled with metformin. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.